Download Databook
Download Sample
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
July 2025
The global strongyloidiasis treatment market size is calculated at USD 1.1 billion in 2024, grows to USD 1.15 billion in 2025, and is projected to reach around USD 1.72 billion by 2034. The market is expanding at a CAGR of 4.5% between 2025 and 2034.
The strongyloidiasis treatment market is witnessing steady growth driven by increasing disease awareness, especially in immunocompromised populations, and rising prevalence in tropical and subtropical regions. The World Health Organization’s support for mass ivermectin administration in endemic areas has boosted treatment efforts. Advancements in diagnostic tools and improved access to generic drugs are enhancing disease management. However, factors like drug resistance and limited healthcare infrastructure in low-income regions remain challenges for broader market expansion.
| Metric | Details |
| Market Size in 2025 | USD 1.15 Billion |
| Projected Market Size in 2034 | USD 1.72 Billion |
| CAGR (2025 - 2034) | 4.5% |
| Leading Region | Latin America share by 42% |
| Market Segmentation | By Drug Type, By Disease Type, By Route of Administration, By Distribution Channel, By End User, By Regions |
| Top Key Players | Merck & Co., Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Strides Pharma Science Ltd., Zydus Lifesciences Ltd., Abbott Laboratories, Bayer AG, Glenmark Pharmaceuticals, Sanofi S.A., Boehringer Ingelheim, Pfizer Inc., Novartis AG, Aurobindo Pharma Ltd., Lupin Pharmaceuticals, Dr. Reddy’s Laboratories, Eisai Co., Ltd., Teva Pharmaceuticals, Johnson & Johnson, Edenbridge Pharmaceuticals |
The market refers to the pharmaceuticals and healthcare services involved in diagnosing and treating Strongyloidiasis, a parasitic infection caused primarily by Strongyloides stercoralis. It is endemic in tropical and subtropical regions and can cause asymptomatic, acute, or life-threatening hyperinfection, particularly in immunocompromised individuals. Treatment relies on anthelmintic drugs, and the market is growing due to increased awareness, improved diagnostics, expansion of mass drug administration (MDA) programs, and the rising global movement of populations from endemic areas.
The strongyloidiasis treatment market is evolving with increased use of ivermectin in mass drug administration programs, supported by WHO guidelines. Advancements in diagnostics, greater disease awareness, and improved access to affordable treatments are enhancing control efforts, especially in endemic regions, despite challenges like drug resistance and infrastructure gaps.
AI can significantly impact the market by improving early detection through advanced diagnostic algorithms and enhancing disease surveillance in endemic areas. It can also accelerate drug discovery and optimize treatment protocols by analyzing large datasets. Furthermore, AI-powered predictive models can help identify high-risk populations, enabling targeted interventions and efficient resource allocation, ultimately improving disease control and treatment outcomes.
Rising Global Prevalence
The increasing number of strongyloidiasis cases worldwide is driving the need for accessible and effective treatment solutions. As the disease becomes more common in vulnerable populations, particularly in low-resource regions, it highlights critical gaps in healthcare. This growth burden is encouraging health agencies to support control strategies, enhance surveillance, and invest in treatment programs, ultimately pushing the market forward to meet the rising demand for better management and prevention of strongyloidiasis.
Limited Healthcare Infrastructure and Access to Diagnostics
Inadequate healthcare infrastructure and limited access to diagnostic services hinder effective management of strongyloidiasis, particularly in resource-poor settings. Many regions lack the necessary tools and skilled personnel to properly identify and treat infections, allowing the disease to persist undetected. This gap in early diagnosis and care reduces treatment success rates and limits the impact of public health interventions, ultimately slowing progress in controlling the spread of the disease and restricting the market growth.
Development of Advanced Diagnostic Tools
Advancements in diagnostic technologies offer a promising opportunity in the strongyloidiasis treatment market by simplifying the identification process of the parasite, even in low-intensity infections. Current diagnostic limitations often lead to underreporting and delayed responses. Enhanced tools can improve detection accuracy, especially in endemic or rural areas, leading to better disease management. These innovations may also support mass screening programs, ultimately increasing the demand for treatment solutions and boosting market growth.
Ivermectin holds a dominant share in the market because of its proven clinical effectiveness and minimal adverse effects. It is used in large-scale treatment campaigns, and endorsement by health organizations has strengthened its clinical credibility. Moreover, its affordability and ease of use in both urban and rural healthcare settings make it a practical option. These combined benefits have made ivermectin the most widely chosen and trusted treatment option for managing strongyloidiasis worldwide.
The moxidectin segment is anticipated to witness the fastest growth in the strongyloidiasis treatment market due to its potential to offer longer-lasting protection and effectiveness in treating chronic infections. Its novel mechanism and promising trial outcomes have attracted attention from researchers and healthcare providers. With increasing efforts to develop alternatives to ivermectin and address drug resistance, moxidectin is gaining traction as a next-generation therapy, driving its accelerated adoption during the forecast period.
The uncomplicated strongyloidiasis segment accounted for the largest market share as it represents the most commonly encountered form of the disease in clinical settings. Its relatively mild symptoms lead to faster diagnosis and early medical intervention, increasing the number of treated cases. Additionally, uncomplicated infections are easier to manage with existing therapies, encouraging wider use. The combination of high case volume and accessible treatment options has significantly contributed to the market expansion.
The hyperinfection syndrome & disseminated strongyloidiasis segment is projected to grow rapidly due to the increasing number of patients with weakened immune systems, such as those undergoing chemotherapy or organ transplants. These individuals are more prone to severe forms of the disease, prompting greater clinical attention and demand for specialized treatments. As medical professionals become more vigilant in managing high-risk infections, this market is gaining traction, leading to a sharp rise in its growth during the forecast period.
The oral segment dominated the market due to its user-friendly nature, cost-effectiveness, and preference among both patients and healthcare providers. It allows for easy administration without the need for specialized equipment or personnel, making it ideal for large-scale use in resource-limited areas. The wide availability contributes to the segment's strong revenue share is expected to support its fastest growth rate in the coming years.
The hospital pharmacies segment held the largest share in the strongyloidiasis treatment market as hospitals are often the first point of care for suspected infections, particularly in acute or high-risk cases. These settings ensure timely diagnosis and prompt access to necessary medications. Moreover, the presence of trained professionals and integrated supply chains within hospitals supports consistent drug availability, making hospital pharmacies a reliable and preferred distribution channel for effective strongyloidiasis treatment.
The online pharmacies segment is projected to experience the highest growth in the strongyloidiasis treatment market as consumers increasingly opt for digital health solutions. The ease of ordering medicines from home, coupled with discreet delivery and expanded drug availability, has boosted their appeal. Moreover, rising smartphone penetration and the growing trust in licensed e-pharmacy platforms are encouraging more patients to purchase treatment online, fueling the market growth during the forecast period.
The hospital & infectious disease clinics segment dominated the market as they are often the first choice for comprehensive care, especially for high-risk or complex cases. These facilities offer specialized expertise, access to advanced treatment protocols, and continuous monitoring, making them essential for managing both routine and severe infections. Their ability to provide immediate and tailored interventions has positioned them as key hubs for treatment, resulting in a large share within the overall market.
The public health organization segment is projected to grow rapidly as global health bodies intensify efforts to combat neglected tropical diseases like strongyloidiasis. These organizations are expanding outreach in remote and high-burden areas, improving access to treatment. Support from international donors, increased screening programs, and integration with national healthcare strategies are accelerating their impact. Their focus on large-scale preventive and therapeutic measures is driving substantial growth in the forecast period.
Latin America dominated the market due to its high disease prevalence, particularly in tropical and subtropical regions where environmental conditions favor parasite transmission. Strong public health initiatives, government-led mass drug administration programs, and increasing awareness have boosted diagnosis and treatment rates. Additionally, collaborations with global health organizations and improved healthcare infrastructure in several countries have enhanced access to effective therapies, positioning Latin America as the leading regional market for strongyloidiasis treatment.
The market in sub-Saharan Africa is expanding due to several key factors. The region's high prevalence of the disease, attributed to poor sanitation and hygiene, has prompted increased attention. The World Health Organization's 2024 guidelines recommend annual mass drug administration of ivermectin in endemic areas, bolstering treatment efforts. Additionally, the availability of affordable, WHO-prequalified generic ivermectin formulations has improved access to treatment, facilitating broader implementation of control programs and driving market growth.
Brazil's market is driven by its high disease prevalence, particularly in tropical regions. Studies indicate significant infection rates among indigenous communities and healthcare professionals, highlighting the need for targeted interventions. Government-led mass drug administration programs, especially using ivermectin, have effectively reduced infection rates. These combined factors underscore Brazil's proactive approach in addressing strongyloidiasis, contributing to the growth of its treatment market.
The market in South Africa faces uncertainty due to limited data on disease prevalence and reliance on low-sensitivity diagnostic methods, leading to underdiagnosis. This hampers accurate assessment and targeted treatment efforts. Additionally, the absence of national control programs and inconsistent access to effective medications like ivermectin contribute to challenges in managing the disease effectively.
Asia-Pacific is expected to grow at the fastest CAGR in the market due to increasing awareness, rising healthcare investments, and improved access to diagnostics and medications. Rapid urbanization and expanding public health initiatives are enhancing disease surveillance and treatment efforts. Additionally, the growing burden of parasitic infections in tropical regions like Southeast Asia is prompting stronger intervention strategies, making the region a key focus for future market expansion and development.
China's market is expanding due to increased detection of cases, particularly in subtropical regions like southern China, where prevalence rates can reach 11–14% among farming communities. Enhanced diagnostic capabilities, growing awareness, and the availability of treatments such as albendazole and ivermectin are driving demand. Additionally, China's expanding pharmaceutical and biotechnology sectors are supporting the development and distribution of antiparasitic therapies, contributing to market growth.
India's market is expanding due to the disease's endemic presence across multiple states, including Delhi, Assam, Tamil Nadu, and Maharashtra. Government initiatives like the National Deworming Day and the Swachh Bharat Abhiyan have enhanced awareness and improved sanitation, contributing to increased detection and treatment efforts. The availability of effective therapies, such as ivermectin, further supports the market's growth.
Europe is expected to experience significant growth in the market during the forecast period, driven by improved screening of migrant populations, the integration of WHO guidelines into national health policies, and increased investment in diagnostic tools. Countries like Italy are adopting cost-effective strategies to manage imported cases. Enhanced awareness, early detection, and access to effective treatments such as ivermectin are collectively driving the region’s proactive approach to controlling the disease.
The UK's market is growing due to increased detection among at-risk groups such as migrants, returning travelers, and immunocompromised individuals. A systematic review identified 1,308 cases, with a significant portion being asymptomatic, underscoring the need for enhanced screening and treatment efforts. Improved diagnostic methods and heightened awareness among healthcare providers are contributing to the market's expansion.
Germany's market is expanding due to increased screening of migrants from endemic regions, as recommended by European health authorities. The adoption of serological testing and the availability of effective treatments like ivermectin have enhanced early detection and management. Additionally, the World Health Organization's 2024 guidelines advocating mass drug administration in endemic areas have influenced Germany's proactive approach to controlling the disease.
In August 2024, InBios International Inc., a key player in diagnostic solutions for emerging diseases, announced the launch of its Strongy Detect IgG ELISA kit—a rapid in vitro serological test designed for presumptive diagnosis of Strongyloides infection. Delivering results in under 75 minutes, the test is CLIA-classified for use in high-complexity labs. According to Dr. Syamal Raychaudhuri, InBios’ Chief Scientific Officer, this test addresses a critical gap in accurately identifying this often-overlooked tropical disease. (Source - Cision)
By Drug Type
By Disease Type
By Route of Administration
By Distribution Channel
By End User
By Region
July 2025
June 2025
July 2025
April 2025